Luminex (LMNX) Reaches $28.56 52-Week High; Akebia Therapeutics, Inc. (AKBA) Had 9 Bullish Analysts

June 1, 2018 - By Linda Rogers

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Logo

The stock of Luminex Corporation (NASDAQ:LMNX) hit a new 52-week high and has $29.99 target or 5.00% above today’s $28.56 share price. The 9 months bullish chart indicates low risk for the $1.27B company. The 1-year high was reported on Jun, 1 by Barchart.com. If the $29.99 price target is reached, the company will be worth $63.45 million more. The stock increased 0.85% or $0.24 during the last trading session, reaching $28.56. About 32,628 shares traded. Luminex Corporation (NASDAQ:LMNX) has risen 33.74% since June 1, 2017 and is uptrending. It has outperformed by 21.17% the S&P500.

Among 11 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Akebia Therapeutics Inc had 25 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 15. Mizuho maintained it with “Buy” rating and $24.0 target in Wednesday, March 7 report. The firm has “Buy” rating by Piper Jaffray given on Monday, December 18. The stock has “Buy” rating by Mizuho on Wednesday, October 4. H.C. Wainwright maintained Akebia Therapeutics, Inc. (NASDAQ:AKBA) rating on Tuesday, December 15. H.C. Wainwright has “Buy” rating and $25.0 target. JMP Securities maintained it with “Market Outperform” rating and $16 target in Wednesday, March 9 report. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) earned “Neutral” rating by Credit Suisse on Thursday, January 21. The company was maintained on Wednesday, August 9 by H.C. Wainwright. Brean Capital initiated the stock with “Buy” rating in Thursday, September 29 report. Morgan Stanley upgraded the shares of AKBA in report on Wednesday, September 9 to “Overweight” rating. See Akebia Therapeutics, Inc. (NASDAQ:AKBA) latest ratings:

07/03/2018 Broker: Mizuho Rating: Buy New Target: $24.0 Maintain
18/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Initiate
07/12/2017 Broker: BTIG Research Rating: Buy New Target: $30.0 Initiate

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide. The company has market cap of $1.27 billion. The company??s products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform. It has a 42.69 P/E ratio. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis.

Among 8 analysts covering Luminex Corp (NASDAQ:LMNX), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Luminex Corp had 16 analyst reports since August 4, 2015 according to SRatingsIntel. Avondale initiated it with “Mkt Outperform” rating and $27 target in Wednesday, October 12 report. The stock of Luminex Corporation (NASDAQ:LMNX) earned “Hold” rating by Jefferies on Friday, June 9. The rating was upgraded by JP Morgan to “Neutral” on Thursday, August 18. Wedbush upgraded the stock to “Outperform” rating in Tuesday, August 4 report. Deutsche Bank upgraded Luminex Corporation (NASDAQ:LMNX) rating on Monday, May 7. Deutsche Bank has “Hold” rating and $2200 target. The stock of Luminex Corporation (NASDAQ:LMNX) earned “Hold” rating by Piper Jaffray on Monday, October 23. The company was maintained on Wednesday, August 5 by Jefferies. The firm has “Hold” rating given on Sunday, September 17 by Piper Jaffray. The stock of Luminex Corporation (NASDAQ:LMNX) earned “Hold” rating by Jefferies on Wednesday, September 13. Jefferies maintained Luminex Corporation (NASDAQ:LMNX) rating on Friday, October 20. Jefferies has “Hold” rating and $21.0 target.

Analysts await Luminex Corporation (NASDAQ:LMNX) to report earnings on August, 6. They expect $0.20 EPS, 0.00% or $0.00 from last year’s $0.2 per share. LMNX’s profit will be $8.89 million for 35.70 P/E if the $0.20 EPS becomes a reality. After $0.25 actual EPS reported by Luminex Corporation for the previous quarter, Wall Street now forecasts -20.00% negative EPS growth.

Since February 15, 2018, it had 0 buys, and 1 insider sale for $14,620 activity. $14,620 worth of Akebia Therapeutics, Inc. (NASDAQ:AKBA) was sold by Nash Duane on Thursday, February 15.

The stock decreased 3.56% or $0.35 during the last trading session, reaching $9.47. About 62,533 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has declined 25.63% since June 1, 2017 and is downtrending. It has underperformed by 38.20% the S&P500.

Another recent and important Akebia Therapeutics, Inc. (NASDAQ:AKBA) news was published by Businesswire.com which published an article titled: “Akebia Therapeutics to Present at Upcoming Investor Conference” on May 15, 2018.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>